Detailed Quote
5i Report
Review of Knight Therapeutics
SEP 21, 2023 - The share price of GUD has declined over the years, while its fundamentals have been mixed. The company maintains a very strong balance sheet and has grown its top line nicely, but its profits have declined over the years leading to a questionable outlook. GUD has been a disappointment for many, us included. Due to some of its fundamentals maintaining their strength (balance sheet, revenue growth), we have kept it in our coverage list, however, we feel it has been held long enough and with declining margins, we are dropping coverage on Knight Therapeutics (GUD).
Download ReportCompany Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Gud seems to be on a bit of a run is there any recent news that your aware of for the new interest and would you change your opinion.
Q: I have held these for quite awhile and I try to be a patient investor but it is challenging. Do you see any catalysts in the 1 to 2 years that might move these stocks significantly higher? The small cap. sector seems to be gaining some interest so I thought these might ride along. thanks
Q: Hello Peter,
Can you please comment on Well health and knight's results? Also, what would be good entry point for Shopify? Thanks very much.
Can you please comment on Well health and knight's results? Also, what would be good entry point for Shopify? Thanks very much.
Insiders
Share Information
News and Media